Table 3.
Simple and multiple regression analysis of factors associated with OR in 73 patients with HCC treated with TACE (patients were divided into two groups: responders and non-responders to TACE).
| Parameters | Responders* | Non-responders* | P value simple analysis | P value multiple analysis |
|---|---|---|---|---|
| Mean age (years) | 67 | 68 | 0.630 | 0.535 |
| Sex (F) | 12/61 (20) | 1/12 (8) | 0.330 | 0.177 |
| PPLE | 31/61 (51) | 1/12 (8) | 0.009 | 0.049 |
| Largest tumor >8 cm | 10/61 (16) | 2/12 (17) | 0.989 | 0.381 |
| Single tumors compared to multiple | 25/61 (41) | 2/12 (17) | 0.089 | 0.196 |
| Unilobar tumors compared to bilobar | 42/61 (69) | 6/12 (50) | 0.474 | 0.797 |
| AFP >400 μg/L | 53/56 (95) | 9/11 (82) | 0.182 | 0.171 |
| Albumin <35 g/L | 33/59 (56) | 9/12 (75) | 0.140 | 0.346 |
| CRP < 10 mg/L | 42/56 (75) | 9/11 (82) | 0.586 | 0.400 |
Values are given as n (%) unless otherwise indicated.
*Responders = OR according to mRECIST.
AFP, alpha-fetoprotein; CRP, C-reactive protein; HCC, hepatocellular carcinoma; mRECIST, modified Response Evaluation Criteria in Solid Tumors; OR, objective response; PPLE, peritumoral portal lipiodol enhancement; TACE, transarterial chemoembolization.